Donna McNamara, MD

Donna McNamara, MD, Co-Chief of the Gynecologic Oncology Division and Medical Oncologist for the Breast Oncology Division at the John Theurer Cancer Center, discusses PARP inhibitors for the treatment of ovarian cancer.

In breast cancer, maintenance drugs exist to keep patients in remission following chemotherapy. There remains a need for such agents in ovarian cancer.

Though only 10-15% of patients harbor a BRCA1/2 mutation, they may see benefit from treatment with a PARP inhibitor.

Videos

Donna McNamara, MD, discusses PARP inhibitors for the treatment of ovarian cancer.

Donna McNamara, MD | Authors

Articles

PARP Inhibitors for Ovarian Cancer